Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 1Hepatitis C, Chronic 1Carcinoma, Hepatocellular 1

Interventions

Brentuximab Vedotin 3relmacabtagene autoleucel 2fludarabine phosphate 2fludarabine 2Cytarabine 2Bortezomib 2Antilymphocyte Serum 2xihuang 1tocilizumab 1tislelizumab 1sofosbuvir-velpatasvir drug combination 1sintilimab 1rasburicase 1ledipasvir 1entecavir 1apatinib 1aflibercept 1acalabrutinib 1Urate Oxidase 1Trabectedin 1Thiotepa 1Thalidomide 1Tenofovir 1Tamsulosin 1Sofosbuvir 1Sevoflurane 1Rivaroxaban 1Ribavirin 1Radiotherapy 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Recurrence × ledipasvir × Clear all
NCT02959359 2017-08-07

DAA in the Risk of Recurrence After Curative Treatment of HCC

Taipei Veterans General Hospital, Taiwan

Phase 4 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡